GPT and metabolic syndrome: Compared with the LPS group, naringenin treatment could effectively improve LPS-induced dyslipidemia in mice, prevent the expression of ALT and AST from rising, and increase the mRNA levels of GCLM and GCLC, indicating that naringenin treatment has a certain therapeutic effect on liver injury.